Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 4/20 | 0.49 |
| ▸ | TNFSF11 | O14788 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765180 | 0.88 | LMNA (0.65) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL2511452 | 0.87 | LMNA (0.53) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL946621 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL1839403 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6769055 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL949716 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL30393652 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6768288 | 0.83 | LMNA (0.59) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6764600 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6764599 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2PLK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1990335-A1 | 17 BETA HSD TYPE 5 INHIBITOR | Astellas Pharma Inc. (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-6716605-B2 | Indole derivatives having an antiviral activity | SHIONOGI & CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| CN-1142909-C | Indole derivatives with antiviral activity | ��Ұ����ҩ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| US-20030181499-A1 | Indole derivatives having an antiviral activity | FUJISHITA TOSHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| US-6506787-B2 | Aids therapy | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| US-20020019434-A1 | Indole derivatives having an antiviral activity | FUJISHITA TOSHIO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6333323-B1 | AS ANTI-HUMAN IMMUNODEFICIENCY VIRUS (HIV) DRUGS | SHIONOGI & CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| CN-1294580-A | Indole derivatives with antiviral activity | SHIONOGI & CO (JP) | 2001-05-09 | — | — | CN | disclosed |
| EP-1069111-A1 | INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | LMNA 475/4885SMN1; SMN2 4578/4885PLK1 1507/4885 |
| US-20020019434-A1 | Indole derivatives having an antiviral activity | IDO1, IDO2, RCOR1 | LMNA 3556/4885SMN1; SMN2 4787/4885PLK1 3827/4885 |
| US-20030181499-A1 | Indole derivatives having an antiviral activity | IDO1, RCOR1, IDO2 | LMNA 3448/4885SMN1; SMN2 4797/4885PLK1 3843/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | LMNA 894/4885SMN1; SMN2 4551/4885PLK1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.